Targeting epigenetic regulation and post-translational modification with 5-Aza-2’ deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy
Journal for ImmunoTherapy of Cancer · 2024-09 · 12 (9) · e008654
DOI: 10.1136/jitc-2023-008654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 26.09.2024. Verfasst von Jessie S Kroonen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Decitabine, Epigenesis, Genetic, Receptors, Antigen, T-Cell. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: KWF Kankerbestrijding.
Abstract (Originalsprache)
Background
Cellular immunotherapy using modified T cells offers new avenues for cancer treatment. T-cell receptor (TCR) engineering of CD8 T cells enables these cells to recognize tumor-associated antigens and tumor-specific neoantigens. Improving TCR T-cell therapy through increased potency and in vivo persistence will be critical for clinical success.
Methods
We evaluated a novel drug combination to enhance TCR therapy in mouse models for acute myeloid leukemia (AML) and multiple myeloma (MM).
Results
Combining TCR therapy with the SUMO E1 inhibitor TAK981 and the DNA methylation inhibitor 5-Aza-2’ deoxycytidine resulted in strong antitumor activity in a persistent manner against two in vivo tumor models of established AML and MM. We uncovered that the drug combination caused strong T-cell proliferation, increased cytokine signaling in T cells, improved persistence of T cells, and reduced differentiation towards exhausted phenotype. Simultaneously the drug combination enhanced immunogenicity of the tumor by increasing HLA and co-stimulation and surprisingly reducing inhibitory ligand expression.
Conclusion
Combining T-cell therapy with TAK981 and 5-Aza-2’ deoxycytidine may be an important step towards improved clinical outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, The Netherlands.
- Department of Hematology, Leiden University Medical Centre, Leiden, The Netherlands.
- Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands.
- Department of Hematology, Leiden University Medical Centre, Leiden, The Netherlands vertegaal@lumc.nl m.h.m.heemskerk@lumc.nl.
- Department of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, The Netherlands vertegaal@lumc.nl m.h.m.heemskerk@lumc.nl.
ORCID-Profile: Jessie S Kroonen, Tassilo L A Wachsmann, Noel F C C de Miranda, Mirjam H M Heemskerk, Alfred C O Vertegaal
Förderung
- KWF Kankerbestrijding
Zitieren
APA
Kroonen, J. S., Wouters, A. K., de Graaf, I. J., Remst, D. F. G., Kumar, S., Wachsmann, T. L. A., Teunisse, A. F. A. S., Roelands, J. P., de Miranda, N. F. C. C., Griffioen, M., Heemskerk, M. H. M., & Vertegaal, A. C. O. (2024). Targeting epigenetic regulation and post-translational modification with 5-Aza-2’ deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy. Journal for ImmunoTherapy of Cancer, 12(9), e008654. https://doi.org/10.1136/jitc-2023-008654
Vancouver
Kroonen JS, Wouters AK, de Graaf IJ, Remst DFG, Kumar S, Wachsmann TLA, et al. Targeting epigenetic regulation and post-translational modification with 5-Aza-2’ deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy. Journal for ImmunoTherapy of Cancer. 2024;12(9):e008654. doi:10.1136/jitc-2023-008654
BibTeX
@article{Kroonen2024,
author = {Kroonen, Jessie S and Wouters, Anne K and de Graaf, Ilona J and Remst, Dennis F G and Kumar, Sumit and Wachsmann, Tassilo L A and Teunisse, Amina F A S and Roelands, Jessica P and de Miranda, Noel F C C and Griffioen, Marieke and Heemskerk, Mirjam H M and Vertegaal, Alfred C O},
title = {Targeting epigenetic regulation and post-translational modification with 5-Aza-2’ deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {9},
pages = {e008654},
doi = {10.1136/jitc-2023-008654}
}
EUVIMED